SuperworthIllumina profit margin ILMN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 18.4%
- Operating margin, 12 months
- 19.6%
- Net margin on a year earlier
- −11.0 pts
- Peer median
- 12.6%
Over the twelve months to Jun 28, 2026, Illumina kept 18.4% of its revenue as net profit, with an operating margin of 19.6% and a gross margin of 66.4%.
Five years earlier its net margin was 19.4%.
The median for 10 diagnostics and research stocks of a similar size is 12.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 19.6% | 18.6% | 66.1% |
| FY2024 | −28.0% | −19.0% | 65.4% |
| FY2023 | −25.8% | −23.8% | 60.9% |
| FY2022 | −96.1% | −91.2% | 64.8% |
| FY2021 | 16.8% | −2.7% | 69.7% |
| FY2020 | 20.3% | 17.9% | 68.0% |
| FY2019 | 28.3% | 27.8% | 69.6% |
| FY2018 | 24.8% | 26.5% | 69.0% |
| FY2017 | 26.4% | 22.0% | 66.4% |
| FY2016 | 19.3% | 24.5% | 69.5% |
| FY2015 | 20.8% | 27.6% | 69.8% |
| FY2014 | 19.0% | 27.7% | 69.7% |
| FY2013 | 8.8% | 9.4% | 64.2% |
| FY2012 | 13.2% | 17.5% | 67.4% |
| FY2011 | 8.2% | 18.9% | 67.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 18.4% | −11.0 pts | 19.6% | |
| Q1 FY26 | 19.4% | +41.7 pts | 19.4% | |
| Q4 FY25 | 19.6% | +47.5 pts | 18.6% | |
| Q3 FY25 | 16.4% | +52.5 pts | 18.2% | |
| Q2 FY25 | 29.4% | +98.1 pts | 30.2% | |
| Q1 FY25 | −22.3% | +6.4 pts | −12.8% | |
| Q4 FY24 | −28.0% | −2.2 pts | −19.0% | |
| Q3 FY24 | −36.1% | −10.9 pts | −26.7% | |
| Q2 FY24 | −68.7% | +25.1 pts | −60.2% | |
| Q1 FY24 | −28.7% | n/a | −24.9% | |
| Q4 FY23 | −25.8% | +70.3 pts | −23.8% | |
| Q3 FY23 | −25.2% | +63.2 pts | −23.1% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.
| Company | Profit margin |
|---|---|
| ILMNIllumina | 18.4% |
| IDXXIDEXX Laboratories | 25.0% |
| WATWaters | 3.6% |
| IQVIQVIA | 8.1% |
| AAgilent Technologies | 19.5% |
| MTDMettler-Toledo International | 21.9% |
| DGXQuest Diagnostics | 9.2% |
| LHLabcorp | 7.0% |
| MEDPMedpace | 17.7% |
| RVTYRevvity | 8.2% |
| DHRDanaher | 15.9% |
| Peer median | 12.6% |
Where Illumina ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Illumina
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.